U.S. Market Advisors Law Group PLLC Alerts Investors of Approaching Lead Plaintiff Deadline in Lawsuit
Against Roche Holding AG
U.S. Market Advisors Law Group PLLC (USMA Law Group) announced today that a securities fraud class action has been filed against
Roche Holding AG (Other OTC: RHHBY). Investors suffering losses from purchases of Roche securities between March 2, 2017 and June
5, 2017, who wish to choose the attorneys to represent you and the class, must apply to be appointed lead plaintiff no later than
August 7, 2017 .
Any member of the proposed class may move the Court to serve as lead plaintiff through attorneys of its choice, or may choose to
do nothing and remain an absent class member. The lead plaintiff will direct the litigation and participate in important decisions
including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants
claiming the largest loss from investment in Roche securities during the relevant period. Members of the class will be represented
by the lead plaintiff and attorneys chosen by the lead plaintiff.
If you would like to discuss your legal rights, click here: http://usmarketlaw.com/roche-securities-class-action/. You may also contact directly attorney David Abel at +1
(202) 274-0237 or info@usmarketlaw.com. There is no cost or obligation to
you.
The lawsuit, Biondolillo v. Roche Holding AG et al., No. 3:17-cv-04056 was filed on June 6, 2017, in the U.S. District
Court for the District of New Jersey. The complaint alleges Roche violated federal securities laws by making fraudulent statements
about the breast cancer drug therapy it is developing. Specifically, defendants allegedly made false and/or misleading statements
and/or failed to disclose that: (1) the combination of drugs Perjeta and Herceptin is only marginally more effective than Herceptin
alone in preventing breast cancer; and (2) as a result, defendants’ statements about the company’s business, operations and
prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On June 5, 2017, media reports publicly revealed that combining Roche’s breast cancer drug Perjeta with its older treatment
Herceptin only had a negligible benefit while the joint therapy significantly increased treatment costs and had higher rates of
certain side effects than Herceptin alone. Roche’s share price dropped following this news.
USMA Law Group is based in Washington, D.C. and represents investors worldwide in U.S. antitrust, securities, and shareholder
litigation. To learn more about USMA Law Group, visit usmarketlaw.com.
This press release may constitute Attorney Advertising in certain jurisdictions.
U.S. Market Advisors Law Group PLLC
David P. Abel, Esq., +1-202-274-0237
info@usmarketlaw.com
usmarketlaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170620005245/en/